Subfoveal Choroidal Thickness as a Potential Predictor of Clinical Response to Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration

Neovascular age-related macular degeneration (nAMD) is one of the leading causes of blindness in individuals older than 50 years of age in industrialized nations.1 The current gold standard for treatment involves intravitreal injections (IVIs) of drugs like aflibercept (Eylea; Regeneron, Tarrytown, NY), bevacizumab (Avastin; Genentech, South San Francisco, CA), and ranibizumab (Lucentis; Genentech, South San Francisco, CA), which primarily target the vascular endothelial growth factor A (VEGF-A).2 However, optimal treatment necessitates continual hospital review and repeated IVIs, which is
Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - Category: Opthalmology Authors: Source Type: research